Search Results - "Uppoor, RS"

Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications by Bhattaram, Venkatesh A, Booth, Brian P, Ramchandani, Roshni P, Beasley, B Nhi, Wang, Yaning, Tandon, Veneeta, Duan, John Z, Baweja, Raman K, Marroum, Patrick J, Uppoor, Ramana S, Rahman, Nam Atiqur, Sahajwalla, Chandrahas G, Powell, J Robert, Mehta, Mehul U, Gobburu, Jogarao V S

“…The value of quantitative thinking in drug development and regulatory review is increasingly being appreciated. Modeling and simulation of data pertaining to…”
Get full text

The Use of Imaging in the Early Development of Neuropharmacological Drugs: A Survey of Approved NDAs by Uppoor, RS, Mummaneni, P, Cooper, E, Pien, HH, Sorensen, AG, Collins, J, Mehta, MU, Yasuda, SU

“…The aim of the study was to evaluate the use of imaging in the development of neuropharmacological drugs. All New Drug Applications (NDAs) approved from 1995…”
Get full text

In vitro metabolic interaction studies: Experience of the Food and Drug Administration by Yuan, Rae, Parmelee, Thomas, Balian, John D., Uppoor, Ramana S., Ajayi, Funmilayo, Burnett, Alfreda, Lesko, Larry J., Marroum, Patrick

“…A total of 194 new molecular entities approved by the Food and Drug Administration between 1992 and 1997 were surveyed to determine the role of in vitro…”
Get full text

Evaluation of "external" predictability of an in vitro-in vivo correlation for an extended-release formulation containing metoprolol tartrate by Mahayni, H, Rekhi, G S, Uppoor, R S, Marroum, P, Hussain, A S, Augsburger, L L, Eddington, N D

“…The purpose of this study was to examine the external predictability of an in vitro-in vivo correlation (IVIVC) for a metoprolol hydrophilic matrix…”
Get more information

In vivo drug-drug interaction studies- A survey of all new molecular entities approved from 1987 to 1997 by Marroum, Patrick J., Uppoor, Ramana S., Parmelee, Thomas, Ajayi, Funmilayo, Burnett, Alfreda, Yuan, Rae, Svadjian, Raffi, Lesko, Lawrence J., Balian, John D.

“…Ninety‐eight new molecular entities applications approved between 1987 to 1991 (period I) and 193 applications for new molecular entities between 1992 to 1997…”
Get full text